# Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

> **NCT00972881** · PHASE1,PHASE2 · COMPLETED · sponsor: **University College, London** · enrollment: 82 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** capecitabine
- **DRUG:** irinotecan hydrochloride
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00972881
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-12
- **Final completion:** 2016-12-31
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00972881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00972881, "Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00972881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*